Loading...
XNAS
ICLR
Market cap12bUSD
Sep 17, Last price  
169.68USD
1D
-2.45%
1Q
16.22%
Jan 2017
125.64%
Name

ICON PLC

Chart & performance

D1W1MN
XNAS:ICLR chart
P/E
56.65
P/S
1.57
EPS
3.00
Div yield, %
Shrs. gr., 5y
8.19%
Rev. gr., 5y
24.15%
Revenues
8.25b
-0.37%
455,597,000630,722,000865,248,000887,612,000900,044,000945,729,0001,115,006,0001,336,058,0001,503,316,0001,574,978,0001,666,487,0001,758,439,0002,595,777,0002,805,839,0002,797,288,0005,480,826,0007,741,386,0008,120,176,0008,281,676,0008,251,340,000
Net income
229m
-71.02%
38,304,00055,963,00078,120,00094,299,00087,071,00022,880,00055,420,000102,812,000172,468,000239,539,000262,179,000281,488,000322,817,000373,986,000327,809,000153,185,000505,304,000612,335,000791,474,000229,339,000
CFO
1.04b
-19.47%
50,452,00042,966,00081,282,000255,070,00087,428,00020,191,000113,771,000221,227,000169,948,000279,531,000259,204,000383,082,000264,013,000412,541,000594,724,000829,142,000563,315,0001,161,027,0001,286,652,0001,036,205,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Related entities

Subsidiaries (6)
ICON Clinical Research Limited
ICON Investments (UK) Limited
ICON INVESTMENTS SIX DESIGNATED ACTIVITY COMPANY
DOCS Resourcing Ltd
ICON CLINICAL RESEARCH INDIA PRIVATE LIMITED
ICON Global Treasury Limited

Key people

Ciaran Murray
Non-Executive Independent Chairman of the Board · since 2021
Chief Financial Officer · since 2024
Barry Balfe
Chief Executive Officer, Chief Operating Officer · since 2025
Diarmaid Cunningham
Chief Administrative Officer, General Counsel, Company Secretary · since 2022
Ronan Murphy
Lead Independent Director · since 2019
Stephen Cutler
Chief Executive Officer, Director · since 2017
John Climax
Independent Director · since 2010
Independent Director · since 2021
Eugene Mccague
Independent Director · since 2017
Independent Director · since 2019
Independent Director · since 2024
IPO date
May 15, 1998
Employees
41,160
Domiciled in
IE
Incorporated in
IE
Headquarters & legal address
South County Business park
Leopardstown
Dublin, D D18X5R3
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT